Immune checkpoint inhibitors (ICI) achieve anti-tumor effects by unlocking the suppressive effect of tumor cells on the immune system and restoring the recognition and killing of tumor cells by T cells.[54] Considering the effectiveness of ICI in cancer treatment, we assessed the sensitivity of GC patients to immunotherapy using anti-PD1 and anti-PDL1 immunotherapy cohorts. Here, PDCD1 is linked to gastric cancer.